Odyssey Health, Inc.
For the period ended Oct 31, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Oct 31, 2025 · Filed Dec 11, 2025
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| For the Three Months Ended October 31, | ||
|---|---|---|
| 2025 | 2024 | |
| General and administrative | $303,190 | $579,427 |
| Loss from operations | (303,190) | (579,427) |
| Loss from change in fair value of Oragenics, Inc. common stock | – | (370,698) |
| Interest expense | (95,336) | (68,781) |
| Financing costs | (507,368) | – |
| Change in fair value of derivative liability | 422,419 | – |
| Other income, net | 28 | – |
| Net loss and comprehensive loss | $(483,447) | $(1,018,906) |
| Basic net loss per share | $(0.00) | $(0.01) |
| Diluted net loss per share | $(0.00) | $(0.01) |
| Shares used for basic net loss per share | 106,036,632 | 104,709,763 |
| Shares used for diluted net loss per share | 106,036,632 | 104,709,763 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.